Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females with Chronic Hepatitis C (HCV) Genotype 1,4,5,6, or indeterminate~* Naive to previous HCV treatment~Exclusion Criteria:~* Positive for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab~* History of any other clinically significant chronic liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+PEG+RBV 12 weeks (Type: EXPERIMENTAL): Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks.
- SOF+PEG+RBV 24 weeks (Type: EXPERIMENTAL): Participants were randomized to receive sofosbuvir+PEG+RBV for 24 weeks.
- SOF+PEG+RBV 12 week/Rerandomization Group (Type: EXPERIMENTAL): Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks, then were rerandomized to receive sofosbuvir only or sofosbuvir+RBV for 12 additional weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).